![[CCO] Certification Coaching Organization LLC](https://www.cco.us/wp-content/uploads/2015/05/CCO-Logo-2015-d3-500px.png "[CCO] Certification Coaching Organization LLC"){kind=logo}
🔍 Definition
Coagulation disorders encompass a broad spectrum of conditions characterized by abnormal hemostasis — either excessive bleeding (hemorrhagic disorders) or pathological clotting (thrombophilia/thrombotic disorders). The hemostatic process requires the coordinated interaction of platelets, the coagulation cascade (intrinsic, extrinsic, and common pathways), and natural anticoagulant systems (protein C, protein S, antithrombin III). Disruption at any point — whether congenital or acquired — produces clinically significant bleeding or thrombosis.
From a coding perspective, coagulation disorders span ICD-10-CM FY2026 category D65–D68 (coagulation defects), D69 (purpura and other hemorrhagic conditions), and D75.82 (heparin-induced thrombocytopenia). Accurate code assignment requires clinical documentation specifying etiology, severity, and relationship to other conditions — especially when anticoagulation therapy is involved.
Coagulation disorders are among the highest-impact diagnoses for HCC v28 Risk Adjustment. D65 (DIC), D66/D67 (Hemophilia A/B), and D68.x variants map to HCC 48 with an RAF weight of approximately 1.018 — one of the highest single-code RAF impacts in the hematology chapter. Failure to document and capture these codes can result in significant revenue leakage for MA plans.
🗂️ Alternative Terminology
Coagulation disorders are documented using a wide variety of clinical and lay terms. The table below maps common clinical terminology to the preferred ICD-10-CM indexable terms.
| Formal / ICD-10-CM Term | Alternative Clinical Names / Lay Terms |
|---|---|
| Disseminated intravascular coagulation (DIC) | Consumptive coagulopathy, defibrination syndrome, DIC syndrome, diffuse intravascular coagulation, microangiopathic coagulopathy |
| Hereditary Factor VIII deficiency (Hemophilia A) | Classic hemophilia, hemophilia A, Factor VIII deficiency, anti-hemophilic factor deficiency |
| Hereditary Factor IX deficiency (Hemophilia B) | Christmas disease, hemophilia B, plasma thromboplastin component deficiency, PTC deficiency |
| Von Willebrand disease (vWD) | vWD, vWF deficiency, von Willebrand factor deficiency, pseudo-hemophilia, angiohemophilia |
| Hereditary Factor XI deficiency (Hemophilia C) | Hemophilia C, Rosenthal syndrome, PTA deficiency, plasma thromboplastin antecedent deficiency |
| Acquired hemophilia | Factor VIII inhibitor, autoimmune hemophilia, acquired Factor VIII inhibitor, acquired coagulation inhibitor |
| Antiphospholipid syndrome (APS) | Hughes syndrome, lupus anticoagulant syndrome, anticardiolipin antibody syndrome, phospholipid antibody syndrome |
| Immune thrombocytopenic purpura (ITP) | Idiopathic thrombocytopenic purpura, immune thrombocytopenia, autoimmune thrombocytopenic purpura, Werlhof disease |
| Heparin-induced thrombocytopenia (HIT) | HIT type II, heparin-associated thrombocytopenia and thrombosis (HATT), white clot syndrome |
| Primary thrombophilia | Inherited thrombophilia, congenital hypercoagulable state, hereditary thrombotic disorder, Factor V Leiden, prothrombin gene mutation |
| Anticoagulant-associated hemorrhage | Warfarin toxicity/bleed, DOAC bleed, anticoagulant-related bleeding, over-anticoagulation, supratherapeutic INR |
🩺 Signs & Symptoms
Clinical presentation varies dramatically based on whether the disorder is hemorrhagic or thrombotic, and whether it is congenital or acquired.
Hemorrhagic Presentations
- Mucocutaneous bleeding: Petechiae, purpura, ecchymosis, mucosal bleeding, epistaxis — typical of platelet disorders (ITP, vWD type 1)
- Deep tissue bleeding: Hemarthrosis (joint bleeding), hematoma, compartment syndrome — typical of factor deficiencies (hemophilia A/B)
- Prolonged or excessive bleeding: Post-procedural/post-traumatic hemorrhage out of proportion to injury
- Spontaneous hemorrhage: Intracranial (I62.9), GI (K92.2), retroperitoneal — indicates severe coagulopathy
- DIC-specific: Simultaneous bleeding from multiple sites (IV sites, wounds, mucosa) plus end-organ signs of microthrombosis
Thrombotic Presentations
- Venous thromboembolism (VTE): DVT, PE — classic for APS, Factor V Leiden, prothrombin gene mutation
- Arterial thrombosis: Stroke (especially in APS), MI, peripheral arterial occlusion
- Microvascular thrombosis: Digital ischemia, livedo reticularis, Raynaud — seen in DIC, HIT, APS
- Recurrent pregnancy loss: Unexplained stillbirth, early fetal loss — strongly associated with APS
- HIT-specific: Paradoxical thrombosis (venous or arterial) despite or after heparin exposure + platelet count drop
Laboratory Abnormalities
- Elevated PT/INR: Extrinsic pathway defects, warfarin effect, liver disease, DIC, vitamin K deficiency
- Elevated PTT: Intrinsic pathway defects (hemophilia A/B/C), heparin effect, lupus anticoagulant, acquired inhibitors
- Thrombocytopenia: ITP, HIT, DIC, drug-induced, bone marrow failure
- Low fibrinogen: DIC (consumption), liver disease, dysfibrinogenemia
- Elevated D-dimer: Active fibrinolysis — sensitive but nonspecific; markedly elevated in DIC
- Low factor levels: Specific factor assays confirm hemophilia subtypes and acquired factor deficiencies
🧭 Differential Diagnosis
Distinguishing among coagulation disorders requires integration of clinical presentation, patient history, and laboratory data. The table below highlights key differentiating features for common coagulopathies.
| Condition | Key Differentiating Features | ICD-10-CM Code |
|---|---|---|
| DIC (Disseminated Intravascular Coagulation) | Underlying trigger (sepsis, OB, trauma, malignancy); simultaneous bleeding + clotting; ↑PT, ↑PTT, ↓fibrinogen, ↑D-dimer, ↓platelets; schistocytes on smear | D65 |
| Hemophilia A | Male; congenital; hemarthrosis/deep bleeds; ↑PTT, normal PT; low Factor VIII activity; family history | D66 |
| Hemophilia B (Christmas disease) | Male; congenital; similar to hemophilia A; normal Factor VIII, low Factor IX | D67 |
| Von Willebrand Disease | Most common inherited bleeding disorder; ↑PTT or normal; low vWF antigen/activity; mucocutaneous bleeding; both sexes | D68.0 |
| Hemophilia C (Factor XI deficiency) | Autosomal recessive; Ashkenazi Jewish population; mild-moderate; ↑PTT; low Factor XI | D68.1 |
| Acquired Hemophilia | Elderly or postpartum women; sudden-onset bleeds; ↑PTT; low Factor VIII, Factor VIII inhibitor present | D68.311 |
| Antiphospholipid Syndrome | Recurrent thrombosis and/or pregnancy loss; positive anticardiolipin Ab, anti-β2GP1, lupus anticoagulant; ↑PTT (paradoxically) | D68.61 |
| Factor V Leiden (Primary Thrombophilia) | Autosomal dominant; VTE risk; resistance to activated protein C; molecular testing confirms | D68.51 |
| ITP (Immune Thrombocytopenic Purpura) | Isolated thrombocytopenia; normal PT/PTT; anti-platelet antibodies; bone marrow shows megakaryocytes; no other cause | D69.3 |
| HIT (Heparin-Induced Thrombocytopenia) | Platelet drop >50% after heparin; 4T score ≥4; HIT-PF4 ELISA + SRA; paradoxical thrombosis; positive result confirms | D75.82 |
| Warfarin/DOAC-Induced Hemorrhage | Active anticoagulant therapy; elevated INR (warfarin) or anti-Xa level (DOACs); bleeding at drug-specific sites | D68.32 |
| Vitamin K Deficiency / Liver Disease | Malnutrition, malabsorption, hepatic failure; ↑PT/INR, ↑PTT; low multiple factors (II, VII, IX, X); responds to vit K | D68.4 |
| Drug-Induced Thrombocytopenia | Recent initiation of offending drug (heparin, quinidine, vancomycin); platelet recovery after drug cessation | D69.59 |
When a patient presents with thrombocytopenia after recent heparin exposure, query the provider to distinguish between HIT (D75.82), ITP (D69.3), and drug-induced thrombocytopenia (D69.59). Each has distinct treatment implications (HIT requires immediate heparin cessation + alternative anticoagulation) and different HCC/CC/MCC mapping. Documentation must support the 4T score criteria for HIT.
📋 Clinical Indicators for Coders/CDI
The following clinical indicators should be present in the medical record before assigning specific coagulation disorder codes. These are not exhaustive but represent minimum documentation standards aligned with CMS ICD-10-CM Official Guidelines FY2026.
| Condition | Required Clinical Indicators | Supporting Lab/Test Evidence |
|---|---|---|
| DIC (D65) | Active bleeding from ≥2 sites; clinical context (sepsis, trauma, OB emergency, malignancy, etc.); provider diagnosis of DIC | Platelet <100K + ↑PT/INR + fibrinogen <100 mg/dL + markedly ↑D-dimer; schistocytes optional but supportive; ISTH DIC score ≥5 |
| HIT (D75.82) | Heparin exposure (any form — IV, SQ, heparin flushes, LMWH); platelet drop >50% from baseline (or nadir <100K); provider diagnosis of HIT; thrombosis may or may not be present | 4T score ≥4 (intermediate/high pretest probability); HIT-PF4 antibody ELISA positive; serotonin release assay (SRA) gold standard; anti-PF4/heparin optical density >1.0 |
| ITP (D69.3) | Isolated thrombocytopenia (platelets typically <100K); provider rules out secondary causes; immune-mediated mechanism documented | Normal PT, PTT; anti-platelet antibodies (not always required); bone marrow normal or increased megakaryocytes; no other etiology identified |
| Acquired Hemophilia (D68.311) | Spontaneous bleeding without prior history; elderly or postpartum; no prior coagulopathy history; provider documents “acquired hemophilia” or “Factor VIII inhibitor” | Markedly ↑PTT not corrected by 1:1 mixing study; low/absent Factor VIII activity; Factor VIII inhibitor titer (Bethesda units) >0.5 BU |
| Anticoagulant Hemorrhage (D68.32) | Active anticoagulant therapy documented; provider links bleeding to anticoagulant effect; supratherapeutic levels or INR | Elevated INR (>3.0 for warfarin); elevated anti-Xa level for DOACs; site of hemorrhage documented (intracranial, GI, etc.) |
| APS (D68.61) | At least one clinical criterion (thrombosis or pregnancy morbidity) + at least one laboratory criterion (positive antiphospholipid antibody on 2 occasions ≥12 weeks apart) | Lupus anticoagulant; anti-cardiolipin IgG/IgM >40 GPL/MPL; anti-β2 glycoprotein-1 >99th percentile; Sapporo criteria met |
| Factor V Leiden / Prothrombin Gene Mutation (D68.51/D68.52) | Molecular testing confirming mutation; clinical context of thrombosis or screening in high-risk patient | Activated protein C resistance testing; factor V Leiden PCR; prothrombin gene 20210A mutation testing |
For D65 (DIC), the code is almost always a secondary diagnosis. Per ICD-10-CM Official Guidelines Section I.C.2, sequence the underlying condition first (e.g., A41.9 sepsis, O45.002 placental abruption with DIC, C80.1 malignancy). Code D65 as additional unless DIC itself is the reason for admission.
🦴 Anatomy & Pathophysiology
Understanding the coagulation cascade is essential for accurate code assignment and CDI query formulation. The hemostatic system operates in three phases:
Primary Hemostasis
Upon vascular injury, subendothelial collagen is exposed. Von Willebrand factor (vWF) bridges collagen to platelet GPIb receptors (adhesion), followed by platelet activation (shape change, granule release) and aggregation via GPIIb/IIIa receptors. Defects in vWF produce von Willebrand disease (D68.0).
Secondary Hemostasis (Coagulation Cascade)
Two pathways converge on the common pathway:
- Intrinsic pathway (contact activation): Factors XII → XI → IX → VIII → X. Measured by PTT. Defects in VIII (hemophilia A, D66), IX (hemophilia B, D67), or XI (hemophilia C, D68.1) prolong PTT without affecting PT.
- Extrinsic pathway (tissue factor pathway): TF-VIIa complex → Factor X. Measured by PT/INR. Vitamin K-dependent factor deficiencies (II, VII, IX, X) prolong PT — defects coded D68.2 or D68.4.
- Common pathway: Factor Xa + Va → prothrombin → thrombin → fibrinogen → fibrin clot. DIC (D65) represents dysregulated activation of this entire system.
Natural Anticoagulant Systems & Thrombophilia
Endogenous anticoagulants prevent pathological clotting: antithrombin III (ATIII) neutralizes thrombin and Xa; Protein C (activated by thrombomodulin-thrombin complex) inactivates Va and VIIIa; Protein S is a cofactor for activated protein C. Deficiency of any of these, or resistance to activated protein C (Factor V Leiden, D68.51), produces primary thrombophilia. Prothrombin gene mutation G20210A (D68.52) increases prothrombin levels and VTE risk.
Pathophysiology of DIC
DIC (D65) is characterized by uncontrolled systemic activation of coagulation triggered by underlying disease (sepsis, trauma, malignancy, obstetric emergency). Tissue factor released from damaged cells activates the extrinsic pathway systemically, generating massive thrombin → widespread microvascular thrombi (end-organ ischemia) + consumption of platelets, fibrinogen, and factors → simultaneous hemorrhage. The ISTH DIC scoring system (platelet count + fibrin markers + PT prolongation + fibrinogen) provides an objective basis for diagnosis.
Pathophysiology of HIT
HIT (D75.82) is an immune-mediated disorder in which heparin binds to platelet factor 4 (PF4), forming an antigenic complex that elicits IgG antibodies. These antibodies activate platelets via FcγRIIa receptors, generating procoagulant microparticles and causing paradoxical thrombocytopenia combined with a markedly elevated thrombotic risk. The 4T scoring system (Thrombocytopenia, Timing, Thrombosis, other causes) is the standard pretest probability tool.
💊 Medication Impact / Treatment
Medications are central to both the etiology and treatment of coagulation disorders. Accurate medication documentation directly affects code assignment (adverse effect vs. therapeutic use, sequencing of D68.32).
Anticoagulant Therapy (Long-Term Status Codes)
| Drug / Class | Long-Term Status Code | Mechanism | Monitoring |
|---|---|---|---|
| Warfarin (Coumadin) | Z79.01 | Vitamin K antagonist; inhibits factors II, VII, IX, X, protein C/S | PT/INR (target 2.0–3.0 most indications) |
| Apixaban, Dabigatran, Rivaroxaban, Edoxaban (NOACs/DOACs) | Z79.02 | Direct factor Xa or IIa (thrombin) inhibitors | Anti-Xa level (apixaban/rivaroxaban/edoxaban); Ecarin clotting time or diluted TT (dabigatran) |
| Aspirin (antiplatelet) | Z79.82 | COX-1 inhibitor; irreversible platelet thromboxane A2 inhibition | Platelet function assay (PFA-100, 85576) |
| Heparin (unfractionated) | Z79.02 or Z79.01 (per payer) | Antithrombin III potentiator; inhibits IIa and Xa | aPTT or anti-Xa (heparin anti-Xa, 85520) |
| LMWH (enoxaparin, dalteparin) | Z79.02 | Primarily anti-Xa activity; some anti-IIa | Anti-Xa level (peak 4h post SQ dose); renal dose adjustment |
Adverse Effect Coding for Anticoagulants
When a patient on anticoagulation develops hemorrhage due to the pharmacologic effect of the drug (even at therapeutic doses), code as adverse effect:
- T45.51xA — Adverse effect of anticoagulants, initial encounter (patient taking drug correctly)
- T45.516A — Underdosing of anticoagulants, initial encounter (patient took less than prescribed — rare cause of thrombosis)
- T45.511A — Poisoning by anticoagulants, accidental (unintentional), initial encounter
Sequencing for anticoagulant-induced hemorrhage: code the site of hemorrhage first, followed by D68.32, then T45.51xA, then Z79.01 or Z79.02 for long-term use status.
Factor Replacement & Hemostatic Agents
- Factor VIII concentrates (J7190–J7192, recombinant J7209–J7211): Hemophilia A and acquired hemophilia
- Factor IX concentrates (J7193–J7195): Hemophilia B
- vWF concentrate (J7184): Type 3 vWD and severe Type 1/2
- Recombinant Factor VIIa (J7212): Hemophilia with inhibitors, acquired hemophilia
- 4-Factor PCC (Kcentra): Warfarin reversal; urgent surgery; Q-code or J-code per payer
- Andexanet alfa (Andexxa/J7169): Direct reversal of Factor Xa inhibitors (apixaban, rivaroxaban)
- Idarucizumab (Praxbind): Dabigatran reversal; J-code or unclassified per payer
- Phytonadione / Vitamin K (J3430): Warfarin reversal, vitamin K deficiency (D68.4)
HIT Treatment
Immediate heparin cessation (all forms) + alternative anticoagulation with direct thrombin inhibitors (argatroban, bivalirudin) or fondaparinux (J1652 Arixtra). LMWH is contraindicated in acute HIT due to cross-reactivity. Warfarin should not be initiated until platelet count recovers to >150K.
Preview ends here. The full guide continues with FY2026 ICD-10-CM code sets, CPT surgical coding, MS-DRG mapping, reimbursement guidance, CDI query templates, and an audit checklist — all available to CCO Members.
← Back to All Clinical Documentation Guides
📘 ICD-10-CM Guidelines (FY2026)
The following guidelines govern code selection and sequencing for coagulation disorders in ICD-10-CM Official Guidelines for Coding and Reporting, FY2026 (effective October 1, 2025).
DIC (D65) Sequencing Rules
Per Official Guidelines Section I.C.2 and Tabular instruction at D65: DIC is coded as an additional/secondary diagnosis unless it is the principal diagnosis (the condition established to be chiefly responsible for the admission). The underlying condition causing DIC must be sequenced first. Common underlying conditions include:
- Sepsis / severe sepsis (A40.x, A41.x) — most common in adults
- Obstetric complications: placental abruption (O45.002), amniotic fluid embolism (O88.119), HELLP syndrome (O14.20)
- Malignancy: solid tumors (e.g., C25.9 pancreatic) or hematologic (C91.00 AML, C94.00)
- Trauma (S/T codes) — especially massive transfusion and polytrauma scenarios
- Transfusion reaction (T80.89xA)
Critical sequencing rule: Code the underlying cause of DIC FIRST. D65 follows as an additional diagnosis. Exception: if DIC is the reason for admission without clear identification of the underlying cause at the time of coding, D65 may be sequenced first. Per Official Guidelines Section II, Selection of Principal Diagnosis, always query the provider when the underlying cause of DIC is not clearly documented.
Anticoagulant-Associated Hemorrhage Sequencing
When a patient on anticoagulant therapy develops hemorrhage as an adverse effect (correctly prescribed and administered), per Official Guidelines Section I.C.19.e:
- Code the nature of the adverse effect (hemorrhage site) first — e.g., I62.9 (intracranial), K92.2 (GI bleeding), N02.9 (recurrent hematuria)
- D68.32 — Hemorrhagic disorder due to extrinsic circulating anticoagulants
- T45.51xA — Adverse effect of anticoagulants, initial encounter
- Z79.01 (warfarin) or Z79.02 (DOAC/heparin) — Long-term drug use status
Thrombophilia Coding Guidelines
Primary thrombophilia codes (D68.51–D68.59) and other thrombophilia codes (D68.61–D68.69) require documentation of the specific type confirmed by laboratory testing. When thrombophilia is diagnosed and a complicating thrombotic event is also present, code both — sequence the acute event (DVT, PE) first, then the thrombophilia as contributing condition. Per Tabular note at D68.5: excludes antiphospholipid syndrome (D68.61) and lupus anticoagulant (D68.62) from this category.
HIT Coding Guidance
Code D75.82 for confirmed HIT (Type II). When HIT is accompanied by thrombosis (HITT), code the thrombotic complication (DVT, PE, arterial) as an additional code to identify the specific site of thrombosis. Per Tabular inclusion note at D75.82: heparin-induced thrombocytopenia (HIT). Heparin-induced thrombocytopenia with thrombosis (HITT) requires additional code for the thrombotic complication. Also assign the adverse effect code T45.515A (adverse effect of anticoagulants, initial encounter — for heparin).
Vitamin K Deficiency / Acquired Factor Deficiency (D68.4)
Code D68.4 for acquired coagulation factor deficiency not elsewhere classified — including liver disease-related coagulopathy and vitamin K deficiency coagulopathy. Excludes vitamin K deficiency of newborn (P53). When due to liver disease, also code the underlying liver disease (K70.x–K77.x); when due to drug effect, follow adverse effect sequencing.
🔢 ICD-10-CM Code Set (FY2026)
All codes verified against CMS FY2026 ICD-10-CM Tabular List, effective October 1, 2025.
D65–D68: Coagulation Defects
| Code | Description | CC/MCC | Notes |
|---|---|---|---|
| D65 | Disseminated intravascular coagulation [DIC] | MCC | Consumptive coagulopathy; always secondary to underlying trigger; sequence underlying cause first. ISTH DIC criteria: platelet ↓ + ↑PT + ↓fibrinogen + ↑D-dimer. Maps to HCC 48, RAF ~1.018. |
| D66 | Hereditary factor VIII deficiency (Hemophilia A) | CC | Classic hemophilia; X-linked recessive; males predominantly affected. Severity: severe <1%, moderate 1–5%, mild 5–40% Factor VIII activity. Maps to HCC 48. |
| D67 | Hereditary factor IX deficiency (Hemophilia B / Christmas disease) | CC | X-linked recessive; same clinical phenotype as hemophilia A; distinguished by factor assay. Maps to HCC 48. |
| D68.0 | Von Willebrand’s disease | CC | Most common inherited bleeding disorder. Types 1 (partial quantitative), 2 (qualitative), 3 (absent vWF). Type 3 most severe. Maps to HCC 48. |
| D68.1 | Hereditary factor XI deficiency (Hemophilia C) | CC | Autosomal recessive; enriched in Ashkenazi Jewish population; variable bleeding phenotype. ↑PTT; Factor XI assay confirms. |
| D68.2 | Hereditary deficiency of other clotting factors | CC | Rare congenital factor deficiencies: II, V, VII, X, XIII, combined vitamin K-dependent factors. Each requires specific factor assay for documentation. |
| D68.311 | Acquired hemophilia | CC | Autoimmune; Factor VIII inhibitor; elderly or postpartum; ↑PTT not correcting on mixing study. Maps to HCC 48. |
| D68.312 | Antiphospholipid antibody with hemorrhagic disorder | CC | Hemorrhagic manifestation in setting of antiphospholipid antibodies. Distinct from APS with thrombosis (D68.61). |
| D68.318 | Other hemorrhagic disorder due to intrinsic circulating anticoagulants, antibodies, or inhibitors | CC | Other acquired inhibitors (anti-Factor IX, anti-Factor X, anti-thrombin). Requires provider documentation of specific inhibitor. |
| D68.32 | Hemorrhagic disorder due to extrinsic circulating anticoagulants | CC | Warfarin, heparin, DOAC-induced hemorrhage (adverse effect). Requires: active anticoagulant therapy + documented hemorrhage + provider link. Maps to HCC 48. Sequence hemorrhage site first, then D68.32, then T45.51xA, then Z79.01/Z79.02. |
| D68.4 | Acquired coagulation factor deficiency | CC | Liver disease-related coagulopathy; vitamin K deficiency; malnutrition. Code underlying cause (K70.x, E56.1) additionally. |
| D68.51 | Activated protein C resistance (Factor V Leiden mutation) | — | Most common hereditary thrombophilia in European descent; confirmed by APC resistance assay + PCR. Maps to HCC 48. |
| D68.52 | Prothrombin gene mutation | — | Factor II G20210A mutation; ↑prothrombin levels; second most common hereditary thrombophilia; PCR confirmation. Maps to HCC 48. |
| D68.59 | Other primary thrombophilia | — | Protein C deficiency, protein S deficiency, antithrombin deficiency, hyperhomocysteinemia (thrombotic). Maps to HCC 48. |
| D68.61 | Antiphospholipid syndrome | — | APS: thrombosis or pregnancy loss + persistent positive antiphospholipid antibodies (Sapporo/Sydney criteria). Maps to HCC 48. |
| D68.62 | Lupus anticoagulant syndrome | — | Positive lupus anticoagulant test; may overlap with APS; paradoxically prolongs PTT in vitro but causes thrombosis in vivo. Maps to HCC 48. |
| D68.69 | Other thrombophilia | — | Includes other thrombotic states not elsewhere classified. Maps to HCC 48. |
| D68.8 | Other specified coagulation defects | — | Dysfibrinogenemia; factor XIII deficiency (acquired); systemic fibrinolysis syndrome. Maps to HCC 48. |
| D68.9 | Coagulation defect, unspecified | — | Avoid if possible — query for specificity. Maps to HCC 48. |
D69: Purpura and Other Hemorrhagic Conditions / Thrombocytopenia
| Code | Description | CC/MCC | Notes |
|---|---|---|---|
| D69.3 | Immune thrombocytopenic purpura (ITP) | CC | Isolated thrombocytopenia; autoimmune platelet destruction; anti-platelet IgG antibodies; normal PT/PTT; treat with steroids, IVIG, TPO-RA (eltrombopag, romiplostim), splenectomy. Maps to HCC 48. |
| D69.41 | Evans syndrome | CC | Simultaneous autoimmune hemolytic anemia + ITP; positive direct Coombs; severe hematologic disease. Maps to HCC 48. |
| D69.42 | Congenital and hereditary thrombocytopenia purpura | CC | MYH9-related disorders, Wiskott-Aldrich syndrome, Bernard-Soulier, gray platelet syndrome; genetic confirmation. |
| D69.49 | Other primary thrombocytopenia | CC | Thrombocytopenia not classified elsewhere in primary category; includes megakaryocytic hypoplasia. |
| D69.51 | Posttransfusion purpura | CC | Sudden severe thrombocytopenia ~7–10 days post-transfusion; anti-HPA-1a antibodies; rare but severe. CC. |
| D69.59 | Other secondary thrombocytopenia | CC | Drug-induced (non-heparin), infection-related, splenic sequestration, bone marrow infiltration. Code underlying cause. |
| D69.6 | Thrombocytopenia, unspecified | CC | Avoid unless no further specificity available; query for etiology (ITP vs secondary vs drug-induced). |
D75.82: Heparin-Induced Thrombocytopenia (HIT)
| Code | Description | CC/MCC | Notes |
|---|---|---|---|
| D75.82 | Heparin-induced thrombocytopenia (HIT) | CC | Immune-mediated; IgG anti-PF4/heparin complex; thrombocytopenia + paradoxical thrombotic risk. Treat with argatroban/bivalirudin. Also assign T45.515A (adverse effect of heparin). Code associated thrombosis additionally (I26.x PE, I82.4x DVT, etc.). Not a standalone HCC but drives HCC-qualifying thrombosis codes. |
Post-Procedural Hemorrhage Codes
| Code | Description | System |
|---|---|---|
| T81.010A | Postprocedural hematoma complicating a procedure, initial encounter | Any system (general) |
| T81.030A | Hemorrhage complicating a procedure, NEC, initial encounter | Any system (general) |
| K91.840 | Postprocedural hemorrhage of digestive system following a procedure | GI |
| K91.841 | Postprocedural hemorrhage of digestive system following other procedure | GI |
| N99.61 | Postprocedural hematoma and seroma of genitourinary system organ following a procedure | GU |
| J95.830 | Postprocedural hemorrhage of respiratory system following a procedure | Respiratory |
| G97.31 | Intraoperative hemorrhage and hematoma of nervous system organ complicating a procedure | Neurological |
| H95.21 | Postprocedural hemorrhage of ear and mastoid following otological procedure | ENT |
| I97.410 | Intraoperative hemorrhage and hematoma of circulatory system organ complicating cardiac bypass | Cardiac |
| M96.830 | Postprocedural hemorrhage of musculoskeletal structure following musculoskeletal surgery | Ortho |
Anticoagulant Status & Adverse Effect Codes
| Code | Description | Use |
|---|---|---|
| Z79.01 | Long-term (current) use of anticoagulants | Warfarin; document therapy status throughout admission |
| Z79.02 | Long-term (current) use of antithrombotics/antiplatelets | DOACs (apixaban, dabigatran, rivaroxaban, edoxaban), LMWH, heparin maintenance |
| Z79.82 | Long-term (current) use of aspirin | Antiplatelet aspirin; dose-dependent (81mg vs 325mg); document indication |
| T45.511A | Poisoning by anticoagulants, accidental, initial encounter | Unintentional overdose (error) |
| T45.512A | Poisoning by anticoagulants, intentional self-harm, initial encounter | Intentional self-harm |
| T45.515A | Adverse effect of anticoagulants (heparin), initial encounter | Heparin adverse effect (HIT, hemorrhage); therapeutic use |
| T45.51xA | Adverse effect of anticoagulants, initial encounter | Warfarin/DOAC adverse effect; use with D68.32 and site of hemorrhage |
| T45.516A | Underdosing of anticoagulants, initial encounter | Patient took less than prescribed; thrombotic event while on anticoagulation |
HIGH RAF IMPACT: HCC 48 (Coagulation Defects) carries an RAF weight of approximately 1.018 under CMS-HCC Model v28 (2026). This is one of the highest single-code RAF contributors in the hematology chapter. Codes mapping to HCC 48 include: D65, D66, D67, D68.0, D68.311, D68.312, D68.318, D68.32, D68.4, D68.51–D68.59, D68.61–D68.69, D68.8, D68.9, D69.3, D69.41, D69.42, D69.49. Validate these codes annually at wellness visits and during inpatient stays. Failure to capture qualifying documentation is a significant RAF gap.
🔎 Indexing
The ICD-10-CM Alphabetic Index provides multiple entry points for coagulation disorders. Key index terms and their index pathways:
| Index Term (Main Term) | Subterm / Qualifier | Code |
|---|---|---|
| Coagulation, intravascular (disseminated) | — (NOS) | D65 |
| Deficiency, factor | VIII (congenital) | D66 |
| Deficiency, factor | IX (congenital) | D67 |
| Disease, von Willebrand | — | D68.0 |
| Hemophilia | (classical) / A | D66 |
| Hemophilia | B (Christmas) | D67 |
| Hemophilia | C (Rosenthal) | D68.1 |
| Hemophilia | acquired | D68.311 |
| Syndrome, antiphospholipid | — | D68.61 |
| Syndrome, lupus anticoagulant | — | D68.62 |
| Thrombophilia | primary, NEC | D68.59 |
| Thrombophilia | Factor V Leiden | D68.51 |
| Mutation, prothrombin gene | — | D68.52 |
| Purpura, thrombocytopenic, idiopathic | — | D69.3 |
| Thrombocytopenia, heparin-induced | — | D75.82 |
| Disorder, hemorrhagic due to anticoagulants | extrinsic circulating | D68.32 |
| Deficiency, coagulation factor, acquired | — | D68.4 |
Indexing tips: When the documentation uses “consumptive coagulopathy” — index to Coagulation, intravascular → D65. “Anti-hemophilic factor deficiency” indexes to Deficiency, factor VIII → D66. “Christmas disease” indexes to Hemophilia, B → D67. “Lupus anticoagulant” alone (lab finding) without clinical syndrome may not qualify for D68.62 — query for clinical context.
🏥 CPT (2026)
CPT codes for coagulation laboratory testing and related procedures are reported under AMA CPT 2026. The following codes are most relevant to coagulation disorder diagnosis and monitoring.
| CPT Code | Description | Clinical Use | Notes |
|---|---|---|---|
| 85610 | Prothrombin time (PT) | Extrinsic/common pathway; warfarin monitoring; INR calculation | Most frequently ordered coag test; bundled with INR |
| 85730 | Thromboplastin time, partial (PTT); activated (aPTT) | Intrinsic pathway; heparin monitoring; hemophilia A/B/C screen; lupus anticoagulant screen | 1:1 mixing study (85732) differentiates factor deficiency from inhibitor |
| 85732 | Thromboplastin time, partial (PTT); substitution, each substrate plasma | Mixing study to differentiate inhibitor vs. factor deficiency | Essential for acquired hemophilia workup |
| 85384 | Fibrinogen; activity | DIC diagnosis/monitoring; liver disease; thrombolytic therapy monitoring | Low (<100 mg/dL) = DIC, dysfibrinogenemia, or liver failure |
| 85385 | Fibrinogen; antigen | Dysfibrinogenemia differentiation | Used when activity-to-antigen ratio needed |
| 85379 | Fibrin degradation products, D-dimer; quantitative | DIC confirmation; PE/DVT rule-out; fibrinolysis monitoring | Highly sensitive for DIC; markedly elevated (>10 µg/mL) in DIC |
| 85378 | Fibrin degradation products, D-dimer; semiquantitative | Point-of-care D-dimer; screening for thrombosis | Less specific than quantitative; negative value rules out PE/DVT in low pretest probability |
| 85049 | Platelet count, manual | Confirm automated low platelet count; morphology review | Always performed when thrombocytopenia suspected or automated count abnormal |
| 85576 | Platelet function (e.g., PFA-100) | vWD screening; aspirin/antiplatelet effect assessment; platelet disorder workup | Closure time (collagen/epinephrine, collagen/ADP cartridges) |
| 85300 | Antithrombin III (AT III); activity | Primary thrombophilia workup (AT III deficiency, D68.59); heparin resistance | Activity assay preferred; antigen level (85301) less sensitive |
| 85301 | Antithrombin III; antigen | Complement to activity assay | — |
| 85302 | Protein C; activity | Protein C deficiency (D68.59); warfarin-related; activated protein C resistance screen | Check after heparin stopped; acute phase reactant can be falsely normal |
| 85303 | Protein C; antigen | Protein C deficiency subtyping (type I vs type II) | — |
| 85305 | Protein S; total | Protein S deficiency (D68.59) | Assess total, free, and functional; affected by pregnancy and OCP |
| 85306 | Protein S; free | Free protein S measurement | — |
| 85307 | Activated protein C (APC) resistance assay | Factor V Leiden screening (D68.51) | Modified APC resistance most specific; confirm with PCR (81240) |
| 85520 | Heparin assay; anti-Xa activity | UFH monitoring; LMWH monitoring; DOAC level (apixaban, rivaroxaban) | Anti-Xa level 4 hours post-SQ LMWH; therapeutic range 0.5–1.0 anti-Xa IU/mL for treatment |
| 85244 | Factor VIII, von Willebrand factor (vWF); activity | vWD diagnosis; vWF ristocetin cofactor activity | — |
| 85245 | Factor VIII related antigen (vWF antigen) | vWD quantitative assessment | Activity/antigen ratio differentiates type 2 vWD subtypes |
| 85247 | Factor VIII related antigen; von Willebrand factor multimers | vWD subtype classification (types 2A, 2B) | Required for vWD subtype determination — affects treatment |
| 85250 | Factor II (prothrombin) clotting activity assay | Prothrombin gene mutation activity; combined factor deficiencies | — |
| 85260 | Factor V (labile factor) clotting assay | Factor V Leiden; factor V deficiency | Low Factor V with low Factor VIII suggests DIC or liver disease |
| 85280 | Factor IX (Christmas factor) clotting assay | Hemophilia B diagnosis and management | — |
| 85270 | Factor VIII clotting assay | Hemophilia A; acquired hemophilia; vWD Type 3 | Used with inhibitor testing (Bethesda titer) |
Individual clotting factor activity assays are reported by CPT 85245–85295 series (each factor has its own specific CPT). When multiple factor assays are ordered, report each separately. For genetic/molecular testing (PCR for Factor V Leiden, prothrombin gene mutation), report CPT 81240 (F2 gene) and 81241 (F5 gene) from the molecular pathology section.
🧾 HCPCS (2026)
HCPCS Level II codes for clotting factor products, anticoagulants, and reversal agents are essential for hospital outpatient, ASC, and home infusion billing. Verify with CMS HCPCS 2026 quarterly updates.
| HCPCS Code | Description | Typical Clinical Use |
|---|---|---|
| J1644 | Injection, heparin sodium, per 1000 USP units | UFH infusion; DVT/PE treatment; procedural anticoagulation; flush (document dose) |
| J1652 | Injection, fondaparinux sodium (Arixtra), 0.5 mg | HIT alternative anticoagulation; VTE prevention and treatment; HIT alternative (no cross-reactivity) |
| J7184 | Injection, von Willebrand factor complex, human (Humate-P, Wilate, Alphanate), per IU vWF:RCo | vWD (all types); acquired vWF syndrome; hemophilia A with vWF component |
| J7190 | Factor VIII (antihemophilic factor, human), per IU | Hemophilia A; plasma-derived factor VIII |
| J7191 | Factor VIII (antihemophilic factor, porcine sequence), per IU | Acquired hemophilia (D68.311) with high-titer inhibitors where human factor bypassed |
| J7192 | Factor VIII (antihemophilic factor, recombinant), per IU | Hemophilia A; recombinant product; prophylaxis and on-demand |
| J7193 | Factor IX complex (e.g., Bebulin, Profilnine), per IU | Hemophilia B; warfarin reversal (3-factor PCC) |
| J7194 | Factor IX (antihemophilic factor B, human), per IU | Hemophilia B; plasma-derived |
| J7195 | Factor IX (antihemophilic factor B, recombinant), per IU | Hemophilia B; recombinant product |
| J7197 | Antithrombin III (human), per IU | Hereditary antithrombin deficiency; DIC (adjunctive); heparin resistance |
| J7198 | Antiinhibitor coagulant complex (FEIBA), per IU | Hemophilia with inhibitors; acquired hemophilia; bypassing therapy |
| J7199 | Hemophilia clotting factor, NOS | Unlisted clotting factor product; submit with invoice |
| J7205 | Injection, efmoroctocog alfa (Eloctate), per IU | Hemophilia A; extended half-life recombinant Factor VIII-Fc fusion |
| J7207 | Injection, lonoctocog alfa (Afstyla), per IU | Hemophilia A; single-chain recombinant Factor VIII |
| J7209 | Injection, nonacog beta pegol (Rebinyn), per IU | Hemophilia B; glycoPEGylated recombinant Factor IX; extended half-life |
| J7210 | Injection, albutrepenonacog alfa (Idelvion), per IU | Hemophilia B; albumin-fused recombinant Factor IX; extended half-life |
| J7212 | Factor VIIa (recombinant), per 1 mcg (NovoSeven RT) | Hemophilia with inhibitors; acquired hemophilia (D68.311); bypassing agent |
| J7169 | Injection, andexanet alfa (Andexxa), 10 mg | Direct Factor Xa inhibitor reversal (apixaban, rivaroxaban); life-threatening/uncontrolled hemorrhage |
| J3430 | Injection, phytonadione (Vitamin K1), per 1 mg | Warfarin reversal; vitamin K deficiency coagulopathy (D68.4); newborn hemorrhagic disease (P53) |
Idarucizumab (Praxbind) for dabigatran reversal: Report with specific J-code if assigned for the billing year; otherwise use unclassified drug code (J3490 or J3590) with invoice. Kcentra (4-Factor PCC) for warfarin reversal: billed by payer-specific J or Q code; confirm with payer prior authorization. Always document the underlying indication (anticoagulant reversal + site of hemorrhage) to support medical necessity.
📚 AHA Coding Clinic (Recent Guidance)
The AHA Coding Clinic provides official guidance on ICD-10-CM code assignment. The following guidance is most relevant to coagulation disorders (cite the specific edition with your facility compliance team):
| Topic | Key Guidance | Approximate Reference Period |
|---|---|---|
| DIC Secondary to Sepsis | Code sepsis as principal diagnosis; D65 as additional code. When sepsis is the underlying cause of DIC, do not code D65 as principal. Query provider when underlying cause is not clearly stated. | Coding Clinic, 4th Qtr guidance (multiple years) |
| Anticoagulant-Induced Hemorrhage | When patient on anticoagulation develops hemorrhage, the hemorrhage code is principal; D68.32 and the appropriate T45.51xA adverse effect code are additional. Adverse effect coding applies even when the drug was therapeutic. | Coding Clinic guidance on adverse effects |
| HIT vs. Drug-Induced Thrombocytopenia | D75.82 is specific to immune-mediated heparin-induced thrombocytopenia. Drug-induced thrombocytopenia from non-heparin drugs is D69.59. The distinction requires clinical documentation. | Coding Clinic, hematology guidance |
| Antiphospholipid Syndrome Coding | Code D68.61 for APS when diagnostic criteria are met (clinical + laboratory). Lupus anticoagulant as isolated laboratory finding may be coded D68.62 when clinically significant and documented by provider. Positive test alone without clinical syndrome does not support D68.61. | Coding Clinic, 3rd Qtr 2020 and related |
| Acquired Hemophilia Sequencing | When acquired hemophilia (D68.311) is present with underlying autoimmune disease (SLE, rheumatoid arthritis), code both; sequence based on reason for admission. | Coding Clinic, hematology guidance |
| Factor V Leiden — Asymptomatic | Code D68.51 when documented by provider even if asymptomatic; it is a reportable condition in all settings when documented. Z-code (Z84.81 family history) is not appropriate when the patient themselves carries the mutation. | Coding Clinic guidance on genetic mutations |
Coding Clinic guidance is available to subscribers at AHA Central Office. Always verify specific edition and page numbers when citing Coding Clinic guidance for audit defense purposes. Guidance above represents the general principles across recent editions; confirm specific Q&A references with your compliance team.
💰 HCC / Risk Adjustment (v28)
HCC mapping uses CMS-HCC Model v28, effective for 2026 payment year. Coagulation disorders represent a high-impact HCC category with RAF weight approximately 1.018 for HCC 48.
HCC 48 (Coagulation Defects and Other Specified Hematological Disorders) carries a risk adjustment factor (RAF) of approximately 1.018 under CMS-HCC v28 — this represents a very significant single-code contribution to a patient’s total RAF score. For Medicare Advantage plans, accurate capture of qualifying coagulation disorder codes translates directly to premium adequacy and care management resources. Annual documentation and coding validation is critical. Codes below are the primary HCC 48 qualifiers.
| ICD-10-CM Code | Description | HCC v28 | RAF Weight (approx.) | CC/MCC Status |
|---|---|---|---|---|
| D65 | DIC (Disseminated Intravascular Coagulation) | HCC 48 | ~1.018 | MCC |
| D66 | Hereditary Factor VIII deficiency (Hemophilia A) | HCC 48 | ~1.018 | CC |
| D67 | Hereditary Factor IX deficiency (Hemophilia B) | HCC 48 | ~1.018 | CC |
| D68.0 | Von Willebrand disease | HCC 48 | ~1.018 | CC |
| D68.1 | Hereditary Factor XI deficiency (Hemophilia C) | HCC 48 | ~1.018 | CC |
| D68.2 | Hereditary deficiency of other clotting factors | HCC 48 | ~1.018 | CC |
| D68.311 | Acquired hemophilia | HCC 48 | ~1.018 | CC |
| D68.312 | APA antibody with hemorrhagic disorder | HCC 48 | ~1.018 | CC |
| D68.318 | Other hemorrhagic disorder due to intrinsic circulating anticoagulants | HCC 48 | ~1.018 | CC |
| D68.32 | Hemorrhagic disorder due to extrinsic circulating anticoagulants | HCC 48 | ~1.018 | CC (when hemorrhage present) |
| D68.4 | Acquired coagulation factor deficiency | HCC 48 | ~1.018 | CC |
| D68.51 | Activated protein C resistance (Factor V Leiden) | HCC 48 | ~1.018 | — |
| D68.52 | Prothrombin gene mutation | HCC 48 | ~1.018 | — |
| D68.59 | Other primary thrombophilia | HCC 48 | ~1.018 | — |
| D68.61 | Antiphospholipid syndrome (APS) | HCC 48 | ~1.018 | — |
| D68.62 | Lupus anticoagulant syndrome | HCC 48 | ~1.018 | — |
| D68.69 | Other thrombophilia | HCC 48 | ~1.018 | — |
| D68.8 | Other specified coagulation defects | HCC 48 | ~1.018 | — |
| D68.9 | Coagulation defect, unspecified | HCC 48 | ~1.018 | — |
| D69.3 | Immune thrombocytopenic purpura (ITP) | HCC 48 | ~1.018 | CC |
| D69.41 | Evans syndrome | HCC 48 | ~1.018 | CC |
| D69.42 | Congenital/hereditary thrombocytopenia | HCC 48 | ~1.018 | CC |
| D69.49 | Other primary thrombocytopenia | HCC 48 | ~1.018 | CC |
| D75.82 | Heparin-induced thrombocytopenia (HIT) | HCC 48 (via sequelae) | Variable (thrombosis codes drive RAF) | CC |
MS-DRG impact: D65 (DIC) as MCC elevates DRG assignment to MCC split, significantly increasing reimbursement. D68.32 as CC elevates DRG to CC split. For common MS-DRGs affected: hematologic disorders with MCC may group to MS-DRG 840 (Lymphoma and Leukemia with MCC); DIC complicating sepsis affects sepsis MS-DRG (871/872/873 splits). Always validate DRG assignment when coagulation disorder codes are present.
✍️ CDI Query Templates
The following query templates comply with AHIMA and ACDIS query guidelines. All queries are non-leading, offer clinically appropriate multiple-choice options, and include “unable to determine” or “other” options.
| # | Clinical Scenario / Trigger | Query Template Wording |
|---|---|---|
| 1 | DIC Clinical Validity Patient has thrombocytopenia, elevated PT/INR, low fibrinogen, and elevated D-dimer in the setting of sepsis. | “The patient has laboratory findings suggesting a consumptive coagulopathy: platelet count [X], PT/INR [X], fibrinogen [X] mg/dL, D-dimer [X] µg/mL, in the setting of [underlying condition]. Based on your clinical assessment, does the patient have: (A) Disseminated intravascular coagulation (DIC), (B) Coagulopathy due to liver disease, (C) Coagulopathy due to massive transfusion, (D) Other: _______, (E) Unable to determine.” |
| 2 | HIT vs. Other Thrombocytopenia Patient’s platelet count drops >50% after heparin initiation; 4T score elevated. | “The patient’s platelet count decreased by [X]% from [baseline] to [nadir] following initiation of heparin on [date]. The 4T score is [X], suggesting [low/intermediate/high] probability. Based on clinical assessment, laboratory results, and/or HIT antibody testing, does the patient have: (A) Heparin-induced thrombocytopenia (HIT), (B) Drug-induced thrombocytopenia (non-heparin), (C) Thrombocytopenia due to [sepsis/DIC/bone marrow suppression], (D) Immune thrombocytopenic purpura (ITP), (E) Other: _______, (F) Unable to determine.” |
| 3 | Anticoagulant-Induced Hemorrhage Linkage Patient on warfarin/DOAC with active hemorrhage; INR or anti-Xa level supratherapeutic or therapeutic. | “The patient is on [warfarin/apixaban/rivaroxaban/dabigatran/edoxaban] and presents with [hemorrhage site and description]. The [INR is X / anti-Xa level is X]. Is the hemorrhage clinically attributable to: (A) Anticoagulant effect (adverse effect of prescribed anticoagulant), (B) Underlying coagulopathy independent of anticoagulant therapy, (C) Structural etiology (e.g., GI lesion, AVM), (D) Both anticoagulant effect and underlying structural cause, (E) Other: _______, (F) Unable to determine.” |
| 4 | Acquired Factor Deficiency Etiology Patient with elevated PT/PTT and low factor levels without prior coagulopathy history; liver disease and nutritional deficiency both present. | “The patient has coagulopathy with [specific lab findings]. Multiple potential etiologies are present in the record: liver disease ([specify stage]), nutritional/vitamin K deficiency, and/or malabsorption. What is the primary cause of the coagulation factor deficiency: (A) Liver disease-related coagulopathy, (B) Vitamin K deficiency, (C) Combined liver disease and vitamin K deficiency, (D) Other acquired coagulation factor deficiency: _______, (E) Unable to determine.” |
| 5 | Thrombophilia Workup Confirmation Patient with VTE and positive thrombophilia workup; provider documentation unclear on whether condition is established diagnosis or screening result. | “The patient’s thrombophilia panel results include [Factor V Leiden PCR positive / prothrombin gene mutation positive / protein C low / protein S low / antithrombin III low]. Based on these results and the clinical presentation, does the patient have a confirmed diagnosis of: (A) Factor V Leiden mutation (activated protein C resistance), (B) Prothrombin gene mutation (Factor II G20210A), (C) Protein C deficiency, (D) Protein S deficiency, (E) Antithrombin III deficiency, (F) Other primary thrombophilia: _______, (G) Positive laboratory finding without clinical diagnosis at this time.” |
| 6 | Antiphospholipid Syndrome vs. Lupus Anticoagulant Patient with positive lupus anticoagulant and/or antiphospholipid antibodies + thrombosis or pregnancy loss. | “The patient has [positive lupus anticoagulant / elevated anticardiolipin IgG or IgM / elevated anti-β2 glycoprotein-1] documented. In the setting of [clinical event: DVT/PE/stroke/fetal loss], does the patient meet criteria for: (A) Antiphospholipid syndrome (APS) — clinical + laboratory criteria met, (B) Lupus anticoagulant syndrome — laboratory finding only, without full APS criteria, (C) Positive antiphospholipid antibodies, clinical significance uncertain, (D) Other thrombophilia: _______, (E) Unable to determine.” |
| 7 | Severity/Clinical Significance of Isolated Lab Abnormality Patient has thrombocytopenia documented only in labs with no provider narrative; platelet count 70K with no bleeding documented. | “The patient’s platelet count is [X] during this [encounter/hospitalization]. Is this thrombocytopenia: (A) Clinically significant and a separately addressable condition requiring or affecting management, (B) An expected/anticipated finding related to [chemotherapy/medications/underlying disease] and not separately coded, (C) Immune thrombocytopenic purpura (ITP), (D) Secondary thrombocytopenia due to [specify]: _______, (E) Other: _______, (F) Unable to determine.” |
Obstetric DIC (e.g., placental abruption, amniotic fluid embolism, HELLP syndrome) requires careful sequencing under Chapter 15 (O codes). The obstetric complication code is sequenced first (e.g., O45.002 for placental abruption with DIC), and D65 may also be coded when DIC is explicitly documented. Query the obstetrician or MFM team to confirm the presence and clinical significance of DIC in all OB emergencies with coagulopathy findings.
🧑⚕️ Treatments (Clinical)
Clinical treatment of coagulation disorders is guided by etiology, severity, and acuity. The following summarizes evidence-based treatment approaches relevant to documentation and coding.
DIC Treatment
- Treat the underlying cause — most critical intervention (antibiotics for sepsis, delivery for obstetric DIC, tumor treatment for malignancy-associated DIC)
- Supportive transfusion: Fresh frozen plasma (FFP, 4F-PCC) for factor replacement; platelet transfusion if <50K with active bleeding; cryoprecipitate for fibrinogen <150 mg/dL; packed red cells for anemia
- Anticoagulation: Low-dose heparin may be considered in thrombosis-predominant DIC (hypercoagulable phase); controversial; document clinical rationale
- ISTH DIC guidelines: Antithrombin concentrate (J7197) in selected cases; recombinant thrombomodulin (investigational in US)
Hemophilia A/B Treatment
- On-demand factor replacement: Target factor level based on bleeding site severity (minor: 30–50%, major: 80–100%)
- Prophylaxis: Regular factor infusions to prevent hemarthrosis and joint damage; standard of care for severe hemophilia
- Emicizumab (Hemlibra): Bispecific antibody mimicking Factor VIII; approved for hemophilia A with and without inhibitors; subcutaneous; monitor with anti-Xa chromogenic assay
- Inhibitor management: Bypassing agents (FEIBA J7198, NovoSeven J7212) or anti-inhibitor approaches (ITI therapy)
ITP Treatment
- Observation: Platelet count >30K without bleeding symptoms; consider watchful waiting
- First-line: Corticosteroids (prednisone, dexamethasone); IVIG (J1572); anti-D immunoglobulin (in Rh-positive patients)
- Second-line: Thrombopoietin receptor agonists (TPO-RA) — eltrombopag (Promacta), romiplostim (Nplate); rituximab; splenectomy
- Emergency/refractory: IV methylprednisolone + IVIG; emergency splenectomy; platelet transfusion (limited efficacy but used in life-threatening bleed)
HIT Management
- Immediate heparin cessation — all forms (IV, SQ, flushes, heparin-coated catheters)
- Alternative anticoagulation: Argatroban (first-line in renal impairment) or bivalirudin; fondaparinux (J1652) in non-critical HIT; danaparoid (if available)
- Warfarin contraindicated in acute HIT until platelet recovery >150K; risk of warfarin-induced limb gangrene
- Duration: Anticoagulate for ≥3 months for HITT; at minimum until platelet count recovery for isolated HIT
Antiphospholipid Syndrome Treatment
- Thrombotic APS: Long-term anticoagulation — warfarin (target INR 2.0–3.0) preferred over DOACs (DOAC inferior in triple-positive APS; TRAPS trial)
- Obstetric APS: Low-dose aspirin + prophylactic LMWH during pregnancy
- Catastrophic APS (CAPS): Anticoagulation + corticosteroids + plasma exchange ± IVIG; mortality ~30%
🎓 Patient Education / Summary
Patient education for coagulation disorders should be tailored to the specific condition, severity, and literacy level. The following points are evidence-based and suitable for clinical documentation of education provided (which also supports medical necessity and discharge planning coding).
For Patients with Bleeding Disorders (Hemophilia, vWD)
- Recognize bleeding warning signs: Unusual bruising, joint swelling or pain, prolonged bleeding from cuts, blood in urine or stool, severe headache (seek emergency care immediately)
- Carry emergency information: Medical alert bracelet or card identifying diagnosis, factor deficiency type, inhibitor status, emergency factor product, treating center contact
- Avoid NSAIDs and aspirin unless explicitly directed by hematologist; use acetaminophen for pain
- Comprehensive Hemophilia Treatment Centers (HTCs): Refer patients to CDC-affiliated HTCs for multidisciplinary care
- Home infusion training: Many patients with hemophilia A/B manage prophylactic infusions at home; document education and training in the medical record
For Patients on Anticoagulation
- Never stop anticoagulants abruptly without provider guidance (risk of rebound thrombosis, especially in APS, mechanical valve)
- Drug and food interactions with warfarin: Consistent vitamin K intake; avoid cranberry juice, grapefruit; report all new medications to prescriber; regular INR monitoring
- DOAC-specific education: Take doses at consistent times; dabigatran requires stomach acid (avoid PPIs); renally cleared — report kidney problems; carry medication card indicating DOAC name and dose for emergency reversal
- Bleeding precautions: Use soft-bristle toothbrush, electric razor; avoid high-contact sports; carry bleeding card (ISTH patient card)
For Patients with ITP
- Platelet count monitoring: Frequency of monitoring depends on count and symptom status; understand that symptoms (not lab value alone) drive treatment decisions for most patients
- Activity restrictions: Avoid contact sports when platelets <50K; discuss with hematologist
- Vaccination precautions: Live vaccines require platelet count ≥50K; consult hematologist before routine vaccinations
- Medication list review: Avoid aspirin, NSAIDs, and other antiplatelet agents unless specifically prescribed
For Patients with Thrombophilia / APS
- Know your type: Understand the specific mutation or antibody found (Factor V Leiden vs. prothrombin gene mutation vs. protein C/S/ATIII deficiency vs. APS) — each has different VTE recurrence risk and management implications
- Anticoagulation adherence: For APS with thrombosis, lifelong anticoagulation is typically indicated; do not stop without hematologist consultation
- Pregnancy planning: Thrombophilia and APS require close coordination with hematology and high-risk OB; do not become pregnant without establishing a management plan
- Family screening: Hereditary thrombophilias (Factor V Leiden, prothrombin gene mutation) warrant consideration of family member screening in appropriate clinical context
About this Guide
This Clinical Documentation Guide is published by CCO Academy and is intended for credentialed coding, CDI, and clinical documentation professionals. Content is updated for FY2026 ICD-10-CM (effective October 1, 2025). All code assignments should be verified against the official ICD-10-CM Tabular List, AHA Coding Clinic, and applicable payer-specific policies. This guide does not constitute legal, medical, or compliance advice.
Last reviewed: April 2026 · Next scheduled review: October 2026 (FY2027 update)
Ready to turn this knowledge into a credential?
These Clinical Documentation Guides are a free companion to CCO’s paid training programs. Browse our full CCO Course, Blitz & Practice Exam Catalog — every core course, review blitz, practice exam, textbook, and free resource in one place — and find the perfect next step for your coding career.
